Literature DB >> 10683292

Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage.

P Menei1, J M Pean, V Nerrière-Daguin, C Jollivet, P Brachet, J P Benoit.   

Abstract

Intrastriatal implantation of genetically modified cells synthesizing nerve growth factor (NGF) constitutes one way to obtain a long-term supply of this neurotrophic factor and a neuronal protection against an excitotoxic lesion. We have investigated if NGF-loaded poly(d,l-lactide-co-glycolide) microspheres could represent an alternative to cell transplantations. These microspheres can be implanted stereotaxically and locally release the protein in a controlled and sustained way. In order to test this paradigm, the NGF release kinetics were characterized in vitro using radiolabeled NGF, immunoenzymatic assay, and PC-12 cells bioassay and then in vivo after implantation in the intact rat striatum. These microspheres were thus implanted into the rat striatum 7 days prior to infusing quinolinic acid. Control animals were either not treated or implanted with blank microspheres. The extent of the lesion and the survival of ChAT-, NADPH-d-, and DARPP-32-containing neurons were analyzed. In vitro studies showed that microspheres allowed a sustained release of bioactive NGF for at least 1 month. Microspheres implanted in the intact striatum still contained NGF after 2.5 months and they were totally degraded after 3 months. After quinolinic acid infusion, the lesion size in the group treated with NGF-releasing microspheres was reduced by 40% when compared with the control groups. A marked neuronal sparing was noted, principally concerning the cholinergic interneurons, but also neuropeptide Y/somatostatin interneurons and GABAergic striatofuge neurons. These results indicate that implantation of biodegradable NGF-releasing microspheres can be used to protect neurons from a local excitotoxic lesion and that this strategy may ultimately prove to be relevant for the treatment of various neurological diseases. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683292     DOI: 10.1006/exnr.1999.7253

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  13 in total

Review 1.  Huntington's disease.

Authors:  S Davies; D B Ramsden
Journal:  Mol Pathol       Date:  2001-12

2.  In vitro and in vivo release of nerve growth factor from biodegradable poly-lactic-co-glycolic-acid microspheres.

Authors:  Ralph de Boer; Andrew M Knight; Robert J Spinner; Martijn J A Malessy; Michael J Yaszemski; Anthony J Windebank
Journal:  J Biomed Mater Res A       Date:  2010-09-28       Impact factor: 4.396

3.  Neurodegenerative diseases: challenges.

Authors:  Vinod Labhasetwar
Journal:  Drug Deliv Transl Res       Date:  2011-10       Impact factor: 4.617

4.  Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease.

Authors:  Brooke R Snyder; Andrew M Chiu; Darwin J Prockop; Anthony W S Chan
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

5.  Nerve growth factor pretreatment attenuates oxygen and glucose deprivation-induced c-Jun amino-terminal kinase 1 and stress-activated kinases p38alpha and p38beta activation and confers neuroprotection in the pheochromocytoma PC12 Model.

Authors:  Rinat Tabakman; Hao Jiang; Erik Schaefer; Robert A Levine; Philip Lazarovici
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Quinolinic acid lesions of the caudate putamen in the rat lead to a local increase of ciliary neurotrophic factor.

Authors:  Stefan Jean-Pierre Haas; Aline Ahrens; Stanislav Petrov; Oliver Schmitt; Andreas Wree
Journal:  J Anat       Date:  2004-04       Impact factor: 2.610

7.  Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease.

Authors:  Dwaine F Emerich; David J Mooney; Hannah Storrie; Rangasamy Suresh Babu; Jeffrey H Kordower
Journal:  Neurotox Res       Date:  2009-07-09       Impact factor: 3.911

Review 8.  Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.

Authors:  Dagmar E Ehrnhoefer; Bibiana K Y Wong; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

Review 9.  Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's Disease.

Authors:  Gary X D'Souza; Henry J Waldvogel
Journal:  J Huntingtons Dis       Date:  2016-12-15

10.  From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF).

Authors:  Claire Géral; Angelina Angelova; Sylviane Lesieur
Journal:  Pharmaceutics       Date:  2013-02-08       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.